Dysregulation of androgen signaling and pericellular proteolysis are necessary for prostate cancer (PCa) progression but the links between them are still obscure. In this study, we show how the membrane-anchored serine protease TMPRSS2 stimulates a proteolytic cascade that mediates androgen-induced PCa cell invasion, tumor growth and metastasis. We found that matriptase serves as a substrate for TMPRSS2 in mediating this pro-invasive action of androgens in PCa. Further, we determined that higher levels of TMPRSS2 expression correlates with higher levels of matriptase activation in PCa tissues. Lastly, we found that the ability of TMPRSS2 to promote PCa tumor growth and metastasis was associated with increased matriptase activation and enhanced degradation of extracellular matrix nidogen-1 and laminin β1 in tumor xenografts. In summary, our results establish that TMPRSS2 promotes the growth, invasion and metastasis of prostate cancer cells via matriptase activation and extracellular matrix disruption, with implications to target these two proteases as a strategy to treat prostate cancer.
Introduction
Prostate cancer (PCa) is the most frequent male malignancy and a leading cause of cancer-related death in many Western countries (1) . In PCa, androgen signaling generally regulates the expression of genes associated with cancer cell growth and survival (2) . Since androgen signaling has been shown to be involved in PCa development and progression (3), androgen deprivation therapy is an option for the patients. Initially, most PCa cells respond to this therapy, but eventually tumors relapse and take on a castration-therapy-resistant PCa phenotype that correlates with poor prognosis and high metastatic potential (4) . Moreover, androgen signaling has been shown to be involved in PCa cell invasion (5, 6) , and strongly implicated in metastasis (3) . However, the detailed molecular mechanisms through which androgen signaling can induce PCa cell invasion and metastasis still need more investigation.
Deregulation of pericellular proteolysis has been proposed to be involved in cancer progression because of its role in the degradation of the extracellular matrix and the alteration of the microenvironment (7) . Recently, several lines of evidence have shown that dysregulation of some membrane-anchored serine proteases (MASPs) contribute to the progression of many human disorders including tumor growth, invasion and metastasis (8) . Among them, matriptase has been focused on because it plays crucial roles in carcinogenesis and cancer cell invasion including PCa (9) (10) (11) (12) . In PCa cells, androgens can induce matriptase activation and shedding (13) . However, the molecular mechanism through which androgens induce matriptase activation and whether the androgen-induced proteolytic cascade plays a role in PCa progression and metastasis are still unknown.
TMPRSS2 is a member of the MASP family (14) and predominantly expressed in prostate (15) . Recent studies have indicated that a gene fusion of the 5′ untranslational region of TMPRSS2 to ETS transcription factors (ERG and ETV1) is often observed in PCa tissues (16) . In addition, TMPRSS2 protein level has been shown to be correlated with PCa progression (17, 18) . However, the in vivo substrate(s) of TMPRSS2 and the TMPRSS2-initiated proteolytic cascade are unknown and the exact role of TMPRSS2 in PCa progression is still unclear. In this report, we addressed the functional role of TMPRSS2 in androgen-induced PCa cell invasion, tumor growth and metastasis, and identified the substrates of TMPRSS2 thus providing a mechanistic explanation of the role of TMPRSS2 in PCa progression.
6 digestion was described in the supplementary information. Peptides were extracted with 50% acetonitrile and dried. The protein identify was revealed by LC/MS/MS (Thermo
LTQ-Velos and ESI-QUAD-TOF).
Cell migration, invasion and wound healing assays. Cell migration and invasion assays were carried out as previously described (11) . For invasion assay, 15 μg Matrigel diluted in 100 μL phenol red-and serum-free RPMI1640 medium were coated to the upper filter of each insert. No Matrigel was coated on the filter for migration assay.
Cells were steroid-starved in a phenol red-free RPMI 1640 medium with 5% cFBS for 24 h and serum-starved for another 24 h. Steroid-and serum-starved cells were seeded at a density of 4×10 various times. SpectraMax M5 (Molecular Devices, Sunnyvale, CA, USA) was used to measure the absorbance at 570 nm.
Western blot. Western blotting was carried out using a standard protocol as previously described (11) . Samples for detection of matriptase (M24 and M69) and HAI-1 (M19) (a gift from Dr. Chen-Yong Lin, Georgetown University Medical Center, Washington DC, USA) were prepared under non-boiling and non-reducing conditions, because these antibodies mainly recognize native protein structures. M24 recognized total matriptase and activated matriptase/HAI-1 complex, and M69 specifically recognized the activated matriptase/HAI-1 complex. M19 recognized free HAI-1 and activated matriptase/HAI-1 complex (21) . To analyze the shedding of matriptase and HAI-1, the conditioned media were collected and concentrated using Amicon Ultra-4 centrifuge filter devices (Millipore), and then analyzed by western blot. For other protein determination, samples were prepared under reducing and denaturing conditions. For the determination of the protease domain of matriptase and TMPRSS2, two polyclonal antibodies against their protease domains were obtained from Calbiochem (CA, USA) and Abcam (MA, USA), respectively. Other primary antibodies used in this study were listed in Table S2 .
Quantitative Real-Time PCR. Quantitative real-time PCR was performed using Maxima SYBR Green/ROX qPCR Master Mix (Thermo, IL, USA), and the expression levels of target genes were statistically calculated with normalization to GAPDH. The primers used in this study were listed in supplemental Table 1 .
Coimmunoprecipitation. HEK293A cells were co-transfected with matriptase and TMPRSS2 plasmids in the presence of HAI-1 plasmids using lipofetamine 2000 (Invitrogen, CA, USA). After transfection, cells were cultured for 48 h and then lyzed in 8 RIPA buffer. Cell lysates were mixed with antibodies against flag or V5 tag and gently rotated at 4°C. Next day, protein A magnetic beads (GE, CT, USA) were added to the mixture for isolating the complexes by rotation for 1 h. After isolation, the protein-bead complexes were washed five times using 0.1 % Tween20 TBS. The precipitated proteins were boiled in 2x Laemmli sample buffer for 10 minutes and subjected to SDS-PAGE and western blot analysis.
TMPRSS2 protease assay. The production of recombinant TMPRSS2 and matriptase proteins were described in detail in supplementary information. The insoluble fractions of LNCaP cells were prepared as described in previous study (22) . For in vitro protease activity and Matrigel degradation assays, recombinant TMPRSS2 proteins (25 ng) were incubated with 100 ng of recombinant matriptase proteins or insoluble fractions of LNCaP cells, or 10 μg Matrigel (BD Biosciences, MA, USA) for 1 h at 37°C in PBS. After electrophoresis, proteins in gel were stained with Coomassie Brilliant Blue G-250 or used for western blot analysis.
Proteolytic activity assay. TMPRSS2-activated matriptase proteolytic activities were examined by the measurement of a fluorescence resonance energy transfer (FRET) of a protease substrate (Boc-Gln-Ala-Arg-AMC, ENZO life science, NY, USA). Purified recombinant matriptase proteins (50 ng) were incubated with or without recombinant wild-type or S441A TMPRSS2 proteins (10 ng) for 1 h at 37°C in PBS. After the incubation, the substrate was added into each sample with a final concentration of 5 μM for the protease activity assay. The proteolytic enzymatic reaction was measured by using an ELISA reader (PARADIGM detection platform, Beckman Coulter, CA, USA) under an excitation wavelength of 380 nm and an emission wavelength of 460 nm for the indicated times. shown to serve as a useful animal model to investigate mechanisms of metastasis (23) .
Sixteen weeks after orthotopic injection, the mice were euthanized and the end-point tumor masses were weighed and statistically calculated with mean±SEM. LNCaP cells with the passage numbers below 40 were used for the experiments since the cells still kept their androgen sensitivity. The passage numbers of the stable pools used for the experiments were within 10 passages, when the first selection of the stable pools was denoted as the first passage for the stable pools.
Immunofluorescence Microscopy. The tumor sections on slides were fixed in 4% paraformaldehyde, and permeabilized using 0.1% Triton-X100 in PBS. Samples were stained with primary antibodies TMPRSS2 (1:500, Abcam), M24 (1:250) and M69
(1:250), and then followed by secondary FITC or Alexa568-conjugated mouse or rabbit antibodies. Nuclei were counterstained with DAPI. Slides were examined and photographed using a Zeiss Axiophot fluorescence microscope.
Immunohistochemical staining of prostate tissue sections. Three human prostate tissue arrays were purchased from US Biomax (Ijamsville, MD). The details about tissue assays were described in the supplementary information. Immunohistochemical staining was carried out as previously described (24) . The immunohistochemical images were scored by the percentage (P) of staining of tumour cells or prostate epithelial cells (0, <10%; 1, 10%-25%; 2, 25%-50%; 3, 50%-75%; 4, >75%) and by the intensity of staining (I) (0, negative staining; 1, weak staining; 2, moderate staining; and 3, strong staining).
The scoring results of each sample were the combination of P plus I values. To define protein expression levels, the scores of ≤3 were classified as belonging to the lowexpression group and the scores above 3 were classified to the high-expression group.
Chi-squared test was used to evaluate the correlation between activated matriptase and TMPRSS2 expression. A two-sided P value of less than 0.05 was considered statistically significant. of less than 0.05 were considered significant in all studies. * denotes a P value less than 0.05; ** denotes a P value less than 0.01; *** denotes a P value less than 0.001. 
Results

Involvement
Identification of TMPRSS2 substrates in PCa cells-To identify putative TMPRSS2
substrate(s) in human PCa cells, we established a stable clone of doxycycline-inducible TMPRSS2-overexpressing LNCaP cells. Upon induction, the expression of exogenous TMPRSS2 proteins was dramatically increased (Fig. 2A) . The conditioned media after the induction were collected for SDS-PAGE and gel staining. The intensities of the four main protein bands were increased in the conditioned media of TMPRSS2-overexpressing cells (Fig. 2B, #1~4 ). These four bands were cut out from the gel for ingel protein digestion and LC/MS/MS analysis. Several membrane-anchored proteins were identified as listed in Fig. 2C and Table S3 . Among them, MASP-matriptase caught our attention as a putative TMPRSS2 substrate owing to its high frequency of appearance and having the same membranous localization as TMPRSS2.
TMPRSS2 induces matriptase activation-To further examine whether TMPRSS2
could induce matriptase activation in PCa cells, we selected two stable clones of TMPRSS2-overexpressing LNCaP cells, and found that the overexpression of TMPRSS2 increased the activated levels of matriptase which formed a 120-kDa complex with HAI-1 and occurred along with reduced levels of latent matriptase (70 kDa) and free HAI-1 (50 kDa) ( Fig. 3A ) with no effect on matriptase and HAI-1 gene expression ( (Fig. S2C) , suggesting that TMPRSS2-induced matriptase activation is a common phenomenon in PCa cells. Overexpression of TMPRSS2 in CWR22Rv1 cells also could enhance the cell invasion and anchorage-independent growth (Fig. S2D&S2E), suggesting that TMPRSS2 plays roles in PCa cell invasion and tumor growth. Moreover, TMPRSS2 silencing significantly decreased the levels of activated matriptase (Fig. 3B) .
To avoid the off-target effects of shRNAs and to confirm the specific role of TMPRSS2 in matriptase activation, we constructed a TMPRSS2-overexpression plasmid with a resistance to shTM2-1 by generating a silent mutation on the shRNA-targeting site. The data showed that the overexpression of TMPRSS2 was able to rescue matriptase activation in the TMPRSS2-knockdown cells (Fig. S2F) . Together, the data strongly indicate that TMPRSS2 plays a role in matriptase activation in human PCa cells.
Matriptase is a substrate of TMPRSS2-To investigate whether matriptase is a substrate of TMPRSS2, we first used pull-down assays to analyze if TMPRSS2 could form a complex with matriptase. The results showed that matriptase could be pulled down by wild-type TMPRSS2 with less affinity by S441A TMPRSS2, and TMPRSS2 could be brought out by matriptase (Fig. 3C ). This suggests that TMPRSS2 can form a complex with matriptase. To further investigate the direct role of TMPRSS2 in the activation of matriptase, we purified recombinant TMPRSS2 proteins with the extracellular regions of wild-type or S441A TMPRSS2 for proteolytic assays. The results showed that recombinant wild-type TMPRSS2 proteins could undergo auto-activation after purification, which was indicated by the release of its protease domain, while S441A TMPRSS2 mutant lost this autoproteolytic property (Fig. 3D, left panel) . Then, the insoluble fraction of LNCaP cell lysate containing matriptase zymogen was mixed with these two recombinant TMPRSS2 proteins. Using a specific antibody against the matriptase protease domain, we found that recombinant wild-type TMPRSS2 but not its protease-null mutant could induce matriptase activation, indicated by the released matriptase's protease domain (26 kDa) (Fig. 3D, right panel) . To further analyze if TMPRSS2 could directly activate matriptase via proteolysis, we performed in vitro proteolytic assays, and found that wild-type recombinant TMPRSS2, but not its protease-null mutant could release the protease domain (26 kDa) of purified recombinant wild-type matriptase (Fig. 3E) . Furthermore, the role of TMPRSS2 in activating the proteolytic activity of matriptase was determined using an in vitro proteolytic assay with a substrate Boc-Gln-Ala-Arg-AMC. The results showed that active TMPRSS2 robustly increased the proteolytic activity of recombinant matriptase, compared to matripase or TMPRSS2 alone (Fig. 3F ). In addition, these two recombinant TMPRSS2 proteins were added into shLuc and shTM2 LNCaP cell cultures. The wildtype recombinant TMPRSS2, but not its protease-null mutant could enhance the activation and shedding of matriptase in shLuc LNCaP cells, and rescue matriptase activation and shedding in shTM2 LNCaP cells (Fig. S3A) . Taken together, these data indicate that TMPRSS2 can activate its substrate matriptase via a direct proteolytic process in PCa cells. (Fig. 4F) . Together, the results indicate that matriptase is important for androgen-induced TMPRSS2 expression that promotes PCa cell invasion.
Identification of extracellular components as substrates of TMPRSS2-To further explore if TMPRSS2 can also proteolytically cleave some components of the extracellular matrix (ECM), the recombinant wild-type or S441A TMPRSS2 proteins (Fig.   5A ) were incubated with matrigel. The result (Fig. 5B) showed that the 160-kDa band was absent after the wild-type TMPRSS2 reaction but not after its protease-null mutant.
The 160-kDa band in the gel was cut out for LC/MS/MS analysis and laminin β1, laminin γ1 and nidogen-1 were identified as putative TMPRSS2's substrates according to their molecular weights ( Fig. 5C and Table S4 ). Immunoblot analysis (Fig. 5D) showed that wild-type TMPRSS2 but not its S441A mutant dramatically decreased the protein levels of nidogen-1 (right panel), partly degraded laminin β1 (left panel) and had no significant effect on laminin γ1 (middle panel). These results imply that TMPRSS2 can proteolytically degrade laminin β1 and nidogen-1 but not laminin γ1, leading to a loose ECM network. To clarify whether there was a role of ECM degradation in TMPRSS2-induced PCa cell invasion or growth, ECM was pre-incubated with recombinant wildtype TMPRSS2 (rTM2) or protease-null TMPRSS2 (rS441A) proteins and then used to coat on transwells for cell invasion assays or for cell proliferation assays. Since PC-3 cells expressed none or little TMPRSS2 (Fig. S3E) 
treated with protease-null rTM2 (S441A). Moreover, TMPRSS2-degraded ECM had no significant effect on PC3 cell proliferation (Fig. 5F ) and matriptase activation (Fig. S3F) .
Thus, the results indicate that the degradation of extracellular matrix by TMPRSS2 plays important role in promoting PCa cell invasion but had no role in TMPRSS2-elicited cell proliferation. Together, the data suggest that in addition to direct induction of matriptase activation, TMPRSS2 also can degrade ECM components, laminin β1 and nidogen-1, contributing to PCa cell invasion. (Fig. 6A) , while the body weights of shTM2 mice were greater than those of shLuc mice (Fig. S4A) . After scarification, the average of the tumor weights was significantly reduced in the shTM2 mice, compared to the control group (Fig. 6B) . We further analyzed the expression of TMPRSS2 and matriptase in the xenograft tumors, and found that the expression level of TMPRSS2 and the activated level of matriptase were remarkably decreased in the whole lysates of shTM2 tumors (Fig. 6C) .
Examination of TMPRSS2 role in tumor growth in vivo-
Immunoflurorescence results further confirmed that a decreased level of TMPRSS2 was observed in shTM2 tumors and occurred in parallel with a reduced level of total and activated matriptase, compared to shLuc tumors ( Fig. 6D and S4B could promote androgen-independent tumor growth, LNCaP cells with overexpression of wild-type TMPRSS2 (TM2), its protease-null mutant (S441A), and control cells (PLKO) were subcutaneously injected into nude mice. To mimic PCa patients receiving androgen ablation therapy, mice were administrated daily with casodex, an antiandrogen reagent. As shown in Fig. 6E , the tumor volumes of TM2 cells grew more quickly than those of PLKO and S441A cells, while the body weights among these three groups showed no significant difference (Fig. S4C) . The average of the tumor volumes was significantly increased in the TM2 group from week 13, compared to the other two groups (Fig. 6E) . Interestingly, the average of S441A tumor weight was significantly reduced in comparison with the control group, suggesting that this TMPRSS2 mutant may exhibit a dominant negative function (Fig. 6F) . We further found that the expression of TMPRSS2 and the activated level of matriptase were increased in TM2 but not S441A tumors (Fig. 6G) . The immunoflurorescence results further showed that both levels of TMPRSS2 and activated matriptase were increased in TM2 tumor tissues compared to PLKO tumors ( Fig. 6H and S4D) . Interestingly, the immunoflurorescence images in S441A xenografted tumors showed that the higher expression of S441A TMPRSS2 correlated with a lower level of activated matriptase (Fig. 6H) , suggesting that S441A TMPRSS2 mutant lacked the ability to proteolytically activate matriptase in tumor lesions, as shown in the in vitro proteolytic assays (Fig. 3E&3F) . Ki67 IHC staining showed that the amounts of Ki67-positive cells were significantly increased in TM2 tumors (Fig. S4E) . In the xenograft tumor lesions, TMPRSS2 significantly reduced the protein level of nidogen-1 and induced the degradation of laminin β1 (80-kDa fragment), while the S441A TMPRSS2 mutant did not act on both proteins (Fig. 6I&S4F) . The data together indicate that TMPRSS2 plays roles in the tumor growth of PCa and promotes androgen-independent cancer growth, which occur in parallel with increased levels of activated matriptase in the tumor lesions. (Fig. 6J) . The average of the orthotopic tumor weights was significantly reduced in the shTM2 group compared to the control group (Fig. S4G) . To further analyze the expression of TMPRSS2 and matriptase in orthotopic and metastatic lesions, the IHC results (Fig. 6K) showed that compared to the primary tumors, increased levels of TMPRSS2 and activated matriptase were observed in metastatic tumor lesions of shLuc mice. The intensities of activated matriptase were reduced in parallel with TMPRSS2 reduction in the primary tumors of the shTM2 group compared to shLuc mice. The effect of TMPRSS2 knockdown on the proliferation of shTM2-1 LNCaP cells was further examined. The results (Fig. S4I) showed that TMPRSS2 silencing exhibited no significant effect on the cell proliferation and the status of matriptase activation, we used IHC to examine the levels of TMPRSS2 and activated matriptase in human PCa specimens. The protein levels of TMPRSS2 were positively correlated with the levels of activated matriptase in the PCa specimens (Fig. 6L&S5A) . Moreover, the levels of TMPRSS2, total matriptase and activated matriptase were increased following cancer progression up to a moderate stage of PCa, but showed a reduced level in poorly differentiated tissues, similar to non-cancerous tissues (Fig. S5B) . Moreover, the results (Fig. S5C) from the overall correlation analysis further showed the levels of TMPRSS2, total matriptase and activated matriptase were significantly increased in the cancerous group compared to the normal group. These findings suggest a strong correlation between the levels of TMPRSS2 and activated matriptase during PCa progression. (27) and also results in the suppression of cell proliferation by androgens (28) . One possibility is that PC-3 cells are not a typical adenocarcinoma of prostate since PC3 cells have been shown with the neuroendocrine cell phenotype (29) . However, the reasons why AR overexpression in PC3 cells reduces the malignant behavior of the cells still remain largely unknown. In this study, our data suggest that androgen signaling exhibits an induction effect on PCa cell invasion via upregulation of its target gene TMPRSS2. In PCa, the expression level of TMPRSS2 has shown a significant increase in malignant cancer tissues compared to benign tissues (18, 30) , while TMPRSS2 expression level in metastatic cancer tissues is not significantly different from that in benign prostatic tissues (18) 
Role of TMPRSS2 in prostate cancer metastasis-
that the protein level of TMPRSS2 is significantly increased in moderately and intermediately differentiated PCa tissues (GS5-6&7) compared to normal prostate tissues. However, there is no statistical difference in TMPRSS2 expression between poorly differentiated tissues (GS8-10) and benign tissues. The results thus indicate that the expression of TMPRSS2 is correlated with PCa progression up to an aggressive but not a metastatic stage, and raised the question of whether TMPRSS2 plays a role in PCa tumor growth and metastasis. Our results from in vivo experiments further verify that TMPRSS2 has a positive role in the tumor growth and metastasis of PCa, and indicate that the elevation of TMPRSS2 in PCa cells also contributes to tumor growth under androgen-ablated conditions. Moreover, in the metastatic lesions of orthotopic xenograft mice, the levels of PSA (Fig S4H) , TMPRSS2 proteins, and activated matriptase were much higher than those in their primary tumors. These data suggest that when PCa cells gain additional androgen signaling to induce TMPRSS2 expression and activated matriptase, those cancer cells are highly metastatic and move out their primary regions to other places. The remaining cancer cells in the primary regions of poorly differentiated PCa only exhibit normal or low androgen signaling that cannot further induce TMPRSS2 expression and matriptase activation. This may explain why the levels of TMPRSS2 expression and matriptase activation in the in situ poorly differentiated PCa tissues become no difference from those in normal prostate tissues.
The data, therefore, suggest that TMPRSS2 has an oncogenic potential to promote PCa progression and metastasis, even in androgen-ablated conditions. 
C4-2B cells suppressed their cell growth (31). Our results (Fig. 6B&S1G) occurs in parallel with matriptase activation and cancer cell invasion (24, 38) . Thus, reduced levels of HAI-1 or HAI-2 contribute to matriptase activation and cancer progression. In this study, we also observed that TMPRSS2 could promote HAI-1 shedding in PCa cells (Fig. S3B) . HAI-1 has been shown to play an important role in the biosynthesis, intracellular trafficking, activation and inhibition of matriptase, with functions as a matriptase's body guard to prevent inappropriate matriptase proteolytic activity during the protease synthesis and trafficking to plasma membrane, as well as a cognate inhibitor for matriptase inhibition after this protease activation (39) In conclusion, our results suggest that the expression of TMPRSS2 induced by androgens can initiates a pericellular proteolytic cascade to activate matriptase that promotes PCa cell invasion. Moreover, TMPRSS2 can also promote PCa tumorigenicity and metastasis, which occurs along with degradation of ECM components, nidogen-1 and laminin β1. Thus, TMPRSS2 can mediate matriptase activation by androgens and disrupt the extracellular matrix network integrity, leading to PCa cell invasion, tumor growth, and metastasis (Fig. 7) . We may explain why TMPRSS2 overexpression or increased matriptase activity following PCa progression is associated with a high metastatic potential and poor prognosis. These data further provide compelling evidence of a serine protease cascade regulated by androgen signaling to promote PCa Purified recombinant TMPRSS2 proteins were incubated with purified recombinant matriptase proteins at 37°C for 1 h. Samples were used for immunoblot analysis using an α-matriptase Ab. F. Analysis of TMPRSS2-induced matriptase proteolytic activity by monitoring the fluorescence signal of Boc-Gln-Ala-Arg-AMC substrate. Measurements were performed in triplicate and represent as means ± SEM. *, P < 0.05. **, P < 0.01. ***, P < 0.001. and M69 mAbs. Nuclei were counterstained with haematoxylin. L. Correlation of TMPRSS2 protein levels with the activated levels of matriptase in archival PCa specimens. *,P < 0.05; **,P < 0.01; ***,P < 0.001. 
